New Drugs in Lung Cancer

1999 ◽  
pp. 249-266
Author(s):  
J. E. Dancey ◽  
F. A. Shepherd
Keyword(s):  
Lung Cancer ◽  
New Drugs

scholarly journals Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer

Biomedicines ◽  
2021 ◽  
Vol 9 (1) ◽  
pp. 48
Author(s):  
Patricia Mondelo-Macía ◽  
Jorge García-González ◽  
Luis León-Mateos ◽  
Adrián Castillo-García ◽  
Rafael López-López ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Liquid Biopsy ◽  
Small Cell ◽  
New Drugs ◽  
Current Status ◽  
Small Cell Lung ◽  
Tumor Biopsy ◽  
Future Utility

Approximately 19% of all cancer-related deaths are due to lung cancer, which is the leading cause of mortality worldwide. Small cell lung cancer (SCLC) affects approximately 15% of patients diagnosed with lung cancer. SCLC is characterized by aggressiveness; the majority of SCLC patients present with metastatic disease, and less than 5% of patients are alive at 5 years. The gold standard of SCLC treatment is platinum and etoposide-based chemotherapy; however, its effects are short. In recent years, treatment for SCLC has changed; new drugs have been approved, and new biomarkers are needed for treatment selection. Liquid biopsy is a non-invasive, rapid, repeated and alternative tool to the traditional tumor biopsy that could allow the most personalized medicine into the management of SCLC patients. Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) are the most commonly used liquid biopsy biomarkers. Some studies have reported the prognostic factors of CTCs and cfDNA in SCLC patients, independent of the stage. In this review, we summarize the recent SCLC studies of CTCs, cfDNA and other liquid biopsy biomarkers, and we discuss the future utility of liquid biopsy in the clinical management of SCLC.

Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.

1990 ◽  
Vol 8 (3) ◽  
pp. 390-395 ◽  
Author(s):  
W K Evans ◽  
E A Eisenhauer ◽  
Y Cormier ◽  
J Ayoub ◽  
R Wierzbicki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Trial Design ◽  
Eastern Cooperative Oncology Group ◽  
Vena Cava ◽  
Small Cell ◽  
New Drugs ◽  
Small Cell Lung ◽  
Investigational Agent

Thirteen previously untreated patients with extensive small-cell lung cancer (SCLC) were treated with the investigational agent amonafide in a dose of 300 mg/m2 intravenously (IV) over 1 hour daily for 5 consecutive days. No responses were seen in 12 eligible patients. Myelosuppression was only occasionally seen. Other toxicities included diaphoresis, chest pain, local irritation at the injection site, arthralgias, nausea and vomiting, and neuromuscular problems. There were two early deaths, both attributable to tumor progression with resultant obstruction of a vital structure. Ten patients crossed over to alternate active therapy (etoposide [VP-16]-cisplatin) and five responded. The median survival time (MST) of the whole group of treated patients was 31 weeks. In future trials of investigational new drugs in previously untreated SCLC, we recommend that patients with the following characteristics be excluded: Eastern Cooperative Oncology Group (ECOG) performance status 2, 3, and 4; superior vena cava (SVC) obstruction; any major paraneoplastic syndrome; serious comorbid illness; and extensive hepatic involvement by tumor. The trial design should include prompt crossover to active alternative therapy, such as VP-16 and cisplatin, for disease progression or for failure to respond after two treatment cycles. Also, the trial design should use an early stopping rule based on interest in identifying only very active agents with a minimum response rate of 30%.

scholarly journals Clerodendrum inerme (L.) Gaertn. Extract Exerts Anticancer Activity on Lung Cancer Cells

2018 ◽  
Vol 17 (2) ◽  
pp. 191-196
Author(s):  
Mahendra Kumar Chouhan ◽  
Pramod Jayadevappa Hurakadle ◽  
Harsha Vasudev Hegde
Keyword(s):  
Lung Cancer ◽  
Cancer Cells ◽  
Morphological Changes ◽  
New Drugs ◽  
Lung Cancer Cells ◽  
Lung Cancer Cell ◽  
Standard Drug ◽  
Efficient Treatment ◽  
Hydroalcoholic Extract ◽  
Antitumor Properties

Cancer is the leading cause of death word wide. Recently there are no new drugs for safe and efficient treatment. Clerodendrum inerme (L.) Gaertn. (Verbenaceae) plant is being used by the ethnic people for cancer treatment. In this study, cytotoxic and antiproliferative potential of hydroalcoholic (methanol and water; 70:30 v/v) extract of C. inerme were evaluated. Various anticancer investigations performed like, lung cancer cell A-549 culture, dye exclusion assay, MTT assay, morphological changes and compatibility with RBC, confirmed the presence of the moiety that have the cytotoxic and antiproliferative potential. Compatibility with RBC was observed, when treated with standard drug doxorubicin, and hydroalcoholic extract of C. inerme at 259.5 μg/ml concentration (IC50). In addition, the same treatment reveled, decrease in cytotoxic efficacy and cell viability against lung cancer cells. Furthermore, change in the cell morphology also suggesting potent antitumor properties of C. inerme. Dhaka Univ. J. Pharm. Sci. 17(2): 191-196, 2018 (December)

New Drugs for Lung Cancer

CHEST Journal ◽  
1986 ◽  
Vol 89 (4) ◽  
pp. 353S-355S
Author(s):  
Rudolf A. Joss
Keyword(s):  
Lung Cancer ◽  
New Drugs

scholarly journals New perspectives in lung cancer.5. New drugs in lung cancer.

Thorax ◽  
1992 ◽  
Vol 47 (3) ◽  
pp. 188-194 ◽  
Author(s):  
D C Talbot ◽  
I E Smith
Keyword(s):  
Lung Cancer ◽  
New Drugs

The Way Forward: New Drugs and New Therapeutic Strategies in Lung Cancer Therapy

2006 ◽  
Vol 7 ◽  
pp. S109-S110
Author(s):  
Giorgio V. Scagliotti ◽  
Silvia Novello
Keyword(s):  
Lung Cancer ◽  
Cancer Therapy ◽  
Therapeutic Strategies ◽  
New Drugs ◽  
Lung Cancer Therapy ◽  
The Way

New drugs for treating small cell lung cancer

Lung Cancer ◽  
1995 ◽  
Vol 12 ◽  
pp. S53-S61 ◽  
Author(s):  
David S. Ettinger
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
New Drugs ◽  
Small Cell Lung

Update on new drugs in small cell lung cancer

2011 ◽  
Vol 20 (4) ◽  
pp. 441-455 ◽  
Author(s):  
Leora Horn ◽  
Emily Louise Castellanos ◽  
David H Johnson
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
New Drugs ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document